suMMARY Changes in the management ofcardiac transplant recipients over the past 10 years have resulted in a substantial improvement in the outlook for survival. Imuran and prednisone remain the primary immunosuppressive agents, but rabbit antihuman thymocyte globulin is used initially and reinstituted during rejection.
Endomyocardial biopsy has allowed more precise diagnosis and management of rejection, and more recently immunological monitoring has been introduced to provide more frequent assessment ofthe host immune response.
Infection is the major cause of death, and its diagnosis and treatment is managed aggressively. Current survival figures justify the use of cardiac transplantation, by an experienced team, when other measures have been exhausted.
Cardiac transplantation was introduced as a therapeutic procedure 11 years ago. It was received with widespread initial enthusiasm and eventually was performed by 66 units throughout the world. Within three years of the clinical advent of heart transplantation, realisation ofthe complex challenges involved in the successful management of cardiac transplant recipients and the generally low survival rates achieved, resulted in the abandonment of the project in all but a few centres. At Stanford University Medical Center an active clinical programme in heart transplantation, initiated in 1968, has continued, however, and the level of activity has steadily increased. By January 1978, a total of 378 cardiac transplantation operations had been performed world wide and 97 patients were then surviving. One hundred and thirty-six of these patients had had their operations at Stanford, with 55 survivors. By the end of 1978 the total number of recipients at Stanford had increased to 161 patients with 67 survivors.
Postoperative management of the recipient has continued to evolve. Changes have resulted from both clinical experience and continuing laboratory research devoted entirely to the study of cardiac 1 This work was supported in part by a grant from the National
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Immunological monitoring
Measurement of circulating levels of T lymphocytes (thymus derived), the putative mediators of cellmediated immune injury, by spontaneous sheep erythrocyte rosette formation has proved to be a sensitive and useful assay for prediction of impending graft rejection (Bieber et al., 1977) . Since the assay can be performed daily, it provides a nearly continuous measure of the host immune status. Early postoperative administration of RATG, prednisone, and azathioprine causes profound depression of circulating T lymphocyte levels. T lymphocyte fractions less than 10 per cent (normally 65% of total circulating lymphocytes) are rarely associated with evidence of graft rejection, and therefore administration of RATG after the routine initial postoperative course is adjusted to maintain measured T lymphocyte fractions below this threshold during the first six postoperative weeks. Rises in T lymphocyte fractions above 10 per cent almost invariably herald overt graft rejection and usually occur one to three days before detectable histological changes. A major limitation of the T cell assay, however, is that after about six weeks there is no longer a close correlation between circulating T cell levels and graft rejection. Circulating T lymphocyte fractions gradually rise towards normal without subsequent graft rejection, therefore nullifying the predictive value of this assay in the later postoperative period.
Total serum rabbit globulin levels in patients treated with RATG can be serially measured by radioimmune assay (Bieber et al., 1975) . The data thus obtained allow characterisation of the disposition kinetics of RATG in individual patients.
During courses of RATG, serum rabbit globulin levels are inversely proportional to T lymphocyte counts; thus, low serum levels of rabbit globulin, resulting from either insufficient dosage or rapid clearance or both, are associated with an increased frequency and severity of rejection episodes and a decrease in late survival rates (Bieber et al., 1977) . Serial measurements of serum rabbit globulin levels are therefore used to determine both dosage and frequency of administration of RATG. Clearance rates do not remain static in individual patients, but usually decrease with repeated RATG courses (Bieber et al., 1976) .
Endomyocardial biopsy
The technique of percutaneous, transvenous endomyocardial biopsy of orthotopic cardiac grafts was developed in the laboratory in 1971 and applied clinically the following year (Caves et al., 1973) . Biopsy is performed by cannulation of the right internal jugular vein with a catheterisation sheath and passage of the biopsy forceps into the right ventricle under fluoroscopic control. Biopsies are usually performed weekly for the first six postoperative weeks, and also when impending rejection is suggested by changes in T lymphocyte levels, serum rabbit globulin levels, or electrocardiographic voltage. Because of its safety endomyocardial biopsy can be performed as frequently as indicated; early histologcal evidence of rejection can therefore be detected before development of graft dysfunction and treatment initiated before irreversible graft damage has occurred. Repeated biopsy also allows objective assessment of the response to antirejection therapy.
Treatment of acute rejection
A rise in the circulating T lymphocyte fraction during the early postoperative period is treated with increased RATG alone if biopsy fails to show histological evidence of acute rejection. If the results of biopsy are positive, however, the oral prednisone dose is increased to 1-5 mg/kg daily (with tapering to baseline levels during the ensuing two weeks) and 1 g methylprednisolone is given intravenously daily for three days. In the presence of adequate white blood cell and platelet counts actinomycin-D is given for two days in doses of 200 ,ug daily and heparin is administered intravenously for three to five days. Resolution of 95 per cent of rejection episodes can be expected with this treatment regimen.
Refractory prolonged acute rejection episodes are managed with additional methylprednisolone, RATG, and further treatment with actinomycin-D if tolerated. Refractory rejection is encountered most often in patients with rapid clearance of rabbit globulin, and for this reason antihuman thymocyte globulin of goat origin has recently been used in such patients. In several cases administration of rabbit and goat ATG on alternate days has resulted in reversal of apparently intractable rejection.
Chronic rejection
After the first three postoperative months the risk of acute graft rejection decreases conspicuously. Later, however, another form of graft injury may appear in the form of obliterative lesions of the donor coronary arteries. The onset of this process is insidious and its pathogenesis is probably related to antibody-mediated injury. Lesions ofthe coronary intima are at first entirely proliferative, but with time develop atherosclerotic characteristics. In order to assess the presence and rate of progression of such lesions coronary arteriography is performed yearly. At present, the incidence of graft arteriosclerosis, including minor disease, is approximately 35 per cent at five years. This incidence is much less than that observed in patients undergoing transplantation before 1970, when indefinite prophylaxis with an antithrombotic regimen consisting of dipyridamole and warfarin was initiated (Griepp et al., 1977b) . Because of its continuing occurrence, serial study is necessary, and six patients have undergone cardiac retransplantation because of critical graft arteriosclerosis. As a result of recent analysis, warfarin has not been used as an item of regular treatment since January 1979, but antiplatelet therapy with dipyridamole has been retained; other regimens of potential benefit are at present being assessed in the laboratory.
Complications of treatment

INFECTION
The majority of deaths after cardiac transplantation in the Stanford series have been the result of infection. One hundred and forty-seven patients suffered from at least one episode of infection. Pulmonary infections are the most common, and cardiac transplant recipients appear to be more prone to such infections than other transplant patients because of preoperative pulmonary congestion, thoracotomy, cardiopulmonary bypass, and endotracheal intubation. Other types of infection encountered in these patients are summarised in Table 1 ; blood stream, central nervous system, and urinary tract infections are also common. Because of the high incidence of infections and the broad range of both ordinary and opportunist pathogens, The incidence of de novo malignant disease after cardiac transplantation is similar in our series to that described for renal transplantation (overall 6%). Thirteen malignant lesions have been diagnosed in the total 161 recipients. These included five carcinomas (four skin, one colon), two cases of acute myeloid leukaemia, and six lymphomas. All the lymphoproliferative diseases occurred in patients whose original diagnosis was idiopathic cardiomyopathy; such patients constitute only 41 per cent of our transplant population (Krikorian et al., 1978) . Moreover, all have been in the younger age range (15 to 30 years). Four patients have died of malignant disease, and the remainder, including four with de novo lymphomas, have survived with appropriate treatment.
Outpatient care
The average hospital stay after transplantation is 55 days. After discharge patients are initially seen twice weekly in the outpatient clinic, and thereafter the frequency of outpatient examination is progressively decreased, in the absence of complications, to once monthly. Patients who remain clinically stable return after two or three months to the care of their referring physicians. Infection and graft rejection are the principal hazards for long-term cardiac recipients. At each outpatient visit, therefore, evidence of such potential complications is sought. Physical findings suggestive of graft rejection include arrhythmias, a diastolic gallop rhythm, a pericardial friction rub, and congestive heart failure. Such findings, either alone or in association with electrocardiographic changes, may require repeat transvenous endomyocardial biopsy on either an outpatient or inpatient basis. Chest x-ray films and electrocardiograms are obtained, and routine biochemical tests include measurement of serum lipids. Hyperlipidaemia, if persistent, is treated with appropriate agents.
Maintenance treatment, other than that required for indefinite immunosuppression, often includes diuretics and supplementary potassium because of the salt-retaining effect of prednisone. The initial treatment of acute rejection episodes diagnosed in the outpatient department on clinical and electrocardiographic criteria (with or without endomyocardial biopsy) generally consists of temporary increase of prednisone dosage to 50 mg twice daily, followed by a daily reduction of the dose by 5 mg to a level 10 mg above prerejection maintenance dosage. Further tapering is accomplished slowly. If complete reversal of signs of acute rejection does not occur within several days, the recipient is admitted for endomyocardial biopsy, and intravenous methylprednisolone and RATG are given as described for early postoperative acute rejection episodes. The maintenance dose of azathioprine is continued according to bone marrow tolerance. Figure. Bieber, C. P., Griepp, R. B., Oyer, P. E., David, L. A., and Stinson, E. B. (1977) . Relationship of rabbit ATG serum clearance rate to circulating T-cell level, rejection onset, and survival in cardiac transplantation. Transplantation Proceedings, 9, 1031-1036. Bieber, C. P., Griepp, R. B., Oyer, P. E., Wong, J., and Stinson, E. B. (1976) . Use of rabbit antithymocyte globulin in cardiac transplantation. Transplantation, 22, 478-488. transplant recipients. 
Current management of cardiac
